New Oncology Drug for reatment of pediatric and young adult patients (age 3-25 years) with relapsed (second or later relapse) B cell precursor acute lymphoblastic leukemia (ALL)? "

Jacob found this article and sent it to me.

It is really great news as there haven't been lots of NEW drugs for
pediatric oncology patients.  Anthony had  Acute Lymphoblastic Leukemia
on the B cell.  I will put a link to this article below.  It is a scientific
medical report, but it is so exciting for me to read.  Several
companies have similar drugs in late stages of development.

This is so exciting for all the children with cancer!

This product is made individually for each patient.

Blood is collected from the patient, and then autologous T cells are separated out and genetically engineered. The process involves inserting a CAR that targets CD19, an antigen expressed on B cells and tumors derived from B cells.  These CAR T cells are then infused back into the patient, who has undergone chemotherapy, and in the body the product homes in on B-cell leukemic cells and destroys them. 

Several similar products are in late stages of development. Coming up soon for review by the FDA is Kite Pharma's axicabtagene ciloleucel (KTE-C19) for lymphoma, while further back are CAR T-cell products from Juno.

A New Dawn: First CAR T Cell Recommended for FDA Approval